At a glance commentaryScientific background on the subject*Chlamydia trachomatis* infection has a high global prevalence and is associated with serious consequences on reproductive health. Antibiotic therapy is not successful at all, thus, vaccine development is strongly needed. One immunogen candidate is Polymorphic Membrane Protein D, a surface protein, highly conserved among serovars, and target of neutralizing antibodies.What this study adds to the fieldThe identification of T- and B-cell epitopes on PmpD allows the selection of several regions that may be used to design subunits vaccines, potentially inducing both humoral and cellular immune responses. Bioinformatics presents powerful tools to the characterization of proteins favoring the rational design of vaccines.

*Chlamydia trachomatis (Ct)* is an intracellular bacterium that is an important cause of sexually transmitted infections (STI) with significant impact on public health. The World Health Organization (WHO) estimates that *Ct* is responsible of almost 106 million of the 500 million new cases of STI reported worldwide annually [@bib1]. *Ct* includes three human biovars composed of different serovars [@bib2] that can infect various cell types in humans. Serovars A-C are responsible for ocular infections that result in trachoma leading to blindness [@bib3]. Serovars D-K causes sexually transmitted diseases such as cervicitis and pelvic inflammatory disease (PID), and globally are an important infectious cause of infertility, ectopic pregnancy [@bib4] and chronic pelvic pain [@bib5] in women. In men it is associated with urethritis, epididymitis and orchitis [@bib6]. Moreover, serovars D-K cause urethritis and neonatal pneumonia [@bib2]. The lymphogranuloma venereum (LGV) serovars L1--L3 not only cause sexually transmitted disease but can also infiltrate local lymph nodes, which ultimately results in systemic infection [@bib7], [@bib8]. *Ct* infections can be controlled by antibiotic therapy but the lack of compliance with treatment, the persistence of the infection even after a complete treatment, together with the high prevalence of asymptomatic cases [@bib4] leading to severe reproductive complications strongly support the development of an effective *Chlamydia* vaccine. Currently, there are no vaccines available against *Ct* genital infection despite the many efforts that have been made throughout the years to develop a protective one. A failure of several vaccine designs may be attributed at least in part to the fact that protective immune response may result harmful for the host and the assumption that complete microorganisms could have components that induce both a protective and a immunopathogenic response. Safety concerns may be overcome by using subunit vaccines, but they require a thorough design in order to be efficient.

Among the antigen candidates that have been studied, members of the Polymorphic Membrane Protein family (Pmp A-I) have shown to be promising as vaccine components as they are dominant antigenic targets for cellular immune responses [@bib9], [@bib10], [@bib11]. Pmps are a group of membrane bound surface exposed chlamydial proteins [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19] that have been characterized as autotransporter adhesins. These proteins are involved in the delivery of virulence factors involved in the initial phase of chlamydial infection [@bib2], disease progression and immune evasion [@bib18]. As typical type V autotransporters [@bib20], all Pmps are characterized by containing conserved GGA (I, L, V) and FxxN tetrapeptide motifs, with an amino-terminal (N-terminal) dependent leader sequence, followed by a passenger domain and a carboxy-terminal (C-terminal) β-barrel [@bib2], [@bib21], [@bib22]. The C-terminal region is incorporated into the outer membrane, forming a pore and allowing the translocation of the N-terminal passenger domain to the bacterial surface [@bib22]. Pmp proteins may also undergo complex infection-dependent post-translational proteolytic processing [@bib8], [@bib17], [@bib18], [@bib23]. These proteins mediate *in vitro* chlamydial attachment to human epithelial and endothelial cells [@bib8], [@bib16].

PmpD is the second highest conserved Pmps demonstrating a 99.1% of amino acid identity among *C. trachomatis* serovars [@bib24], and it is a target of broadly cross-reactive neutralizing antibodies [@bib16]. The structural features of PmpD are relatively large size (1530 aa, 160.5 kDa), integrin-binding RGD motif (aa 698 to 670), and a putative nuclear localization signal (NLS; aa 783 to 798) [@bib18] besides of N-terminal GGA(I/L/V) and FxxN tetrapeptide repeats as in all Pmps.

Due to its conserved nature, surface localization, and immunological importance PmpD is an attractive vaccine candidate for the prevention of human infections [@bib16]. However, it has a high molecular weight with a complex structure which makes it difficult to handle by recombinant DNA techniques. Thus, an in-depth study of the molecule is needed in order to make a rational choice of the immunogen taking into consideration the critical epitopes to induce the appropriate immunological reaction. Several authors suggest that immunity against *C. trachomatis* requires CD4+ T cells, (mainly Th1) with INF-γ production and, to a lesser degree CD8+ T cells. Besides, neutralizing antibodies are now the focus of immune protection and vaccine development [@bib16]. One of the major difficulties in developing an effective chlamydial vaccine is identifying the B-cell epitopes and the MHC-bound chlamydial protein epitopes that are recognized by T-cells.

In this context, bioinformatic approaches can contribute to the design of epitope-based vaccines. Therefore, the aim of this study was to perform *in silico* prediction of B and T epitopes within the amino acid sequence of PmpD for the design of a subunit vaccine against *C*. *trachomatis*.

Materials and methods {#sec2}
=====================

Datasets {#sec2.1}
--------

An amino acid sequence of *C*. *trachomatis* serovar L2 PmpD available from NCBI (Genbank [AAK69391.2](ncbi-p:AAK69391.2){#intref0015}) [@bib25] was used for computational prediction. PmpD genes are one the most conserved between *C. trachomatis* serovars (with 99.1% similarities at the amino acid sequence level) [@bib24]. This was confirmed by Clustal Omega, an algorithm of multiple amino acid sequence alignment available at <http://www.ebi.ac.uk/Tools/msa/clustalo/>.

3D structure prediction {#sec2.2}
-----------------------

The online tool integrated at Raptor X (<http://raptorx.uchicago.edu/>) was used for homology modeling of the PmpD in order to predict B cell epitopes in 3D conformation. Raptor X is a protein structure prediction server for protein sequences without close homologs in the Protein Data Bank (PDB) (Källberg et al., 2012). The server uses PSI-BLAST to find homologue templates and model the 3D structure on the basis of solvent accessibility, secondary and tertiary structures, and disordered regions. The following confidence scores are used to indicate the quality of a predicted 3D model: P-value for the relative global quality and uGDT (un-normalized GDT) for the absolute global quality.

Moreover, programs for structural analysis were used to check the 3D model. ANOLEA was used for energy calculations at the atomic level in protein structure [@bib26] and RAMPAGE to generate the Ramachandran plot, showing protein residues in the favored, allowed and outliers regions [@bib27].

B-cell epitope prediction {#sec2.3}
-------------------------

### Linear B-cell epitope prediction {#sec2.3.1}

BepiPred was used to determine B cell linear epitope of PmpD. It is a method made by combining the predictions of a hidden Markov model and the propensity scale by Parker et al. [@bib28], [@bib29]. BepiPred assigns a score value to each protein residue. The method\'s specificity and sensitivity depend on the score threshold. For this analysis the threshold of 0.35 was employed. BepiPred is available at [www.cbs.dtu.dk/services/BepiPred](http://www.cbs.dtu.dk/services/BepiPred){#intref0030}.

### Discontinous B-cell epitopes {#sec2.3.2}

DiscoTope was employed to predict the surface epitopes on a globular structure. The method is based on amino acid statistics, spatial information, and surface accessibility considering Parker\'s hydrophilicity value [@bib29]. These analyses are carried out taking into account a compiled data set of discontinuous epitopes determined by X-ray crystallography of antibody/antigen protein complexes [@bib30], [@bib31]. The updated version of DiscoTope is available at [www.cbs.dtu.dk/services/DiscoTope-2.0](http://www.cbs.dtu.dk/services/DiscoTope-2.0){#intref0035}.

T-cell epitope prediction {#sec2.4}
-------------------------

NetMHC [@bib32], [@bib33], [@bib34] version 3.4 and NetMHCII [@bib35], [@bib36] version 2.2 were used for T-cell epitope linked to mayor histocompatibility complex (MHC) I or MHC II alleles prediction, respectively. The predictions are based on artificial neural networks (ANN). The servers are free to use and available at: <http://www.cbs.dtu.dk/services/NetMHC> and <http://www.cbs.dtu.dk/services/NetMHCII>.

Results {#sec3}
=======

3D structure prediction {#sec3.1}
-----------------------

PmpD modeling was performed using Raptor X, which makes alignments between a target sequence and one or multiple distantly related template proteins (especially those with sparse sequence profiles) and employs a nonlinear scoring function and a probabilistic-consistency algorithm [@bib37].

The Raptor X software modeled 1398 residues of 1530 (91%) of the PmpD sequence and identified four domains. To model domains 1 and 4, Raptor X used the passenger domain of the *Escherichia coli* autotransporter EspP (PDB entry: 3sze A) as a template, rhamnogalacturonase A from *Aspergillus aculeatus* (PDB entry: 1rmg A) as a template of domain 2, and autotransporter EstA from *Pseudomonas aeruginosa* (PDB entry: 3kvn A) as a template of domain 3. The software predicts that the protein has β sheets (31%), some α helices structure (9%) and several loops (58%) ([Fig. 1](#fig1){ref-type="fig"}A). According to the prediction, a 34% of PmpD is exposed to the surface while a 22% of PmpD is half exposed and a 43% is buried. The model seems to be good quality as suggested by confidence scores assigned by the software: P-value = 2.59 × 10^−17^, and uGDT = 409.Fig. 1**3D structure of PmpD.** (A) Molecular model obtained with Raptor X. (B) Conformational B-cell epitopes predicted by DiscoTope (cyan regions).

Additional checking was performed with ANOLEA and RAMPAGE. ANOLEA analysis indicated that 45% of amino acids modeled by Raptor X have high energy. Ramachandran plot showed that 91.3% residues in the PmpD model were within the most favored regions, 5.8% residues in the allowed region and 2.9% residues in the outlier region. Homology modeling was also performed with Phyre [@bib38] and Swiss-Model [@bib39] softwares. However, unlike Raptor X, these only predicted the β barrel forming a single domain (data not shown).

B-cell epitope prediction {#sec3.2}
-------------------------

### Linear B-cell epitope prediction {#sec3.2.1}

BepiPred predicted 48 B-cell linear epitopes (that have more than four residues) with a sensitivity and a specificity of 75% and 50%, respectively. As can be seen in [Fig. 2](#fig2){ref-type="fig"}, these epitopes are abundant and are homogeneously distributed throughout the protein sequence. Forty motifs characteristic of Pmps (21 GGA and 19 FxxN) are present in the amino acid sequence, ten of them are included in epitope regions (sequences are highlighted in bold (FxxN) and underlined (GGA) in [Fig. 2](#fig2){ref-type="fig"}). Larsen et al. found that BepiPred had the highest prediction accuracy on the test data set, and it was shown to perform significantly better than all other methods tested on the validation data set [@bib28], [@bib40].Fig. 2**PmpD amino acid sequence.** BepiPred predicted 48 B-cell linear epitopes (highlighted in gray). FxxN motifs are indicated in bold, GGA sequences are underlined.

### Discontinous B-cell epitopes {#sec3.2.2}

DiscoTope identified 57 residues, as part of epitope regions. A threshold of −3.7 for epitope identification was selected; therefore B-cell discontinuous epitopes were predicted with 0.75 specificity and 0.47 sensitivity. As the theory predicts, conformational epitopes were observed in loops, mainly in the regions not included in the β-barrel domain (C-terminal) ([Fig. 1](#fig1){ref-type="fig"}B).

Although confidence scores assigned by Raptor X indicated a good quality model, the reliability of the 3D model was further analyzed at the localization of the predicted conformational epitopes. The analysis performed by ANOLEA indicated that 85% of the 57 residues have high energy. The Ramachandran plot showed that 86% of the epitope residues are included in favorable regions, 12.3% in permitted regions and 1.7% in outlier regions.

T-cell epitope prediction {#sec3.3}
-------------------------

The ability of an epitope for binding to MHC molecules is expressed as IC50 value (nM). Strong binding peptides (SB) have an IC50 value below 50 nM, and weak binding peptides (WB) an IC50 value between 50 and 500 nM. The location of T-cell epitopes with strong and weak affinity for human MHC-I and MHC-II alleles was predicted using IEDB resource. As can be seen in [Table 1](#tbl1){ref-type="table"}, NetMHC predicted 271 T-cell epitopes of different lengths (9aa, 10aa, 11aa, 12aa) with weak affinity to molecules of MHC I and 70 T-cell epitopes of different lengths (9aa, 10aa, 11aa, 12aa) with strong affinity to molecules of MHC I ([Table 1](#tbl1){ref-type="table"}A). On the other hand, NetMHCII predicted 2903 T-cell epitopes of 15aa with weak affinity and 742 T-cell epitopes of 15aa with strong affinity to molecules of MHC class II for the most prevalent MHC alleles in Argentina according to Perusco et al. [@bib40] ([Table 1](#tbl1){ref-type="table"}B). These epitopes are abundant and are homogeneously distributed throughout the protein sequence. Multiple alleles of MHC Class II are able to bind the same epitope. This was observed with several epitopes.Table 1(A) Number of T-cell epitopes of different lengths (9aa, 10aa, 11aa, 12aa) predicted with Strong Binding (SB) and Weak Binding (WB) to MHC class I. (B) Number of T-cell epitopes of 15aa predicted with Strong Binding (SB) and Weak Binding (WB) to MHC class II.AMHC class I Prediction9aa10aa11aa12aaSBWBSBWBSBWBSBWBHLA-A\*02:011425420115721HLA-B\*35:0193311710261022HLA-B\*35:0310010001HLA-C\*07:0121531131246HLA-C\*07:02010010112014BMHC class II Prediction15aaSBWBHLA-DRβ1\*01:01375619HLA-DRβ1\*04:0139479HLA-DRβ1\*04:0440442HLA-DRβ1\*04:0547365HLA-DRβ1\*07:0199402HLA-DRβ1\*11:0120264HLA-DRβ1\*13:02122332

Vaccine candidates {#sec3.4}
------------------

Giving that potential B- and T-cell epitopes were found to be distributed throughout the whole sequence, numerous fragments could be selected as candidates for the design of a vaccine. Nevertheless, it is necessary to define both B- and T-cell epitopes as candidates, to thereby generate a vaccine inducing both humoral and cellular response. Therefore, a more exhaustive analysis was performed to identify regions comprising both types of epitopes. The analysis consisted of simultaneously comparing the results obtained by the predictors. As shown in [Table 2](#tbl2){ref-type="table"}, residues of several epitopes have been identified simultaneously by four predictors: BepiPred (linear B-cell), DiscoTope (conformational B-cell), NetMHC (T-cell for MHCI) and NetMHCII (T-cell for MHC II). The data indicate that there are six regions with epitopes predicted by at least two predictors ([Table 2](#tbl2){ref-type="table"}, [Fig. 3](#fig3){ref-type="fig"}). An additional analysis of sequence conservancy showed that these regions are conserved among serovars, with the exception of aa 782 (V in serovars A-C, and A in serovars D-L). Regarding other proteins from the PmpD family, there is a variable degree of similarity among the selected fragments and PmpA, -B, -C, -E, -F, and -H (0--55%), and with Pmp21 from *Clamydia pneumoniae* (15--55%). No significant similarity was observed with human proteins.Table 2B- and T-cell epitopes that include residues predicted simultaneously by at least two predictors among BepiPred (B-cell lineal), DiscoTope (B-cell conformational), NetMHCI (T-cell for MHCI) and NetMHCII (T-cell for MHCI) are highlighted in bold. Core amino acids of MHC II peptides are underlined.RegionsLinear B-cell epitopesConformational B-cell epitopesT-cell epitopes for MHC II (SB)T-cell epitopes for MHC I (WB)1**PSSFQEKDADTLPGKVE**\
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Discussion {#sec4}
==========

*C*. *trachomatis* is the leading cause of bacterial sexually transmitted disease worldwide. Despite the fact that antibiotic treatment is effective in eliminating the pathogen, up to a 70% of all infections are asymptomatic. Untreated *Chlamydia* infections can lead to severe reproductive problems. Several *C. trachomatis* vaccine designs have been tested, but unfortunately there is no vaccine for *Chlamydia* despite the many efforts that have been made throughout the years. In part, this is due to an incomplete understanding of the immune response to *Chlamydia* urogenital infection [@bib41] and of the critical immune factors required for resolving infections and protecting against reinfection [@bib42], [@bib43]. Many researchers suggest that both humoral and cell mediated immunity for a successful Chlamydia vaccine are required. Olsen et al. [@bib44] describe that the primary role of neutralizing antibodies will be to reduce initial infectious load once intra-cellular, remaining bacteria can be targeted by a bactericidal cell mediated immune (CMI) response. For this reason, a rationally designed *Chlamydia* vaccine requires identification of optimal cell T- and B-cell antigens. Considering that the immunoinformatics is a discipline which can predict *a priori* whether an antigen is immunogenic through epitope prediction, our aim was to perform *in silico* prediction of B- and T-cell epitopes within the amino acid sequence of PmpD for the design of a subunit vaccine against *C*. *trachomatis*.

In the present study, different tools were used to analyze antigenic epitopes for PmpD of *C*. *trachomatis*. The complete amino acid sequence of PmpD was acquired from the data base of NCBI (<http://www.ncbi.nlm.nih.gov/>) corresponding to serovar L2. PmpD is one of the most conserved protein among *C. trachomatis* serovars (with 99.1% similarity at the amino acid sequence level) [@bib24]. We confirmed that serovars A to L share 99--100% identity of amino acid sequence by Clustal Omega (Multiple Alignment).

Considering that PmpD plays a critical role in chlamydial biology and pathogenesis, particularly at early host--cell interaction [@bib45], it is very important to determine the presence and localization of B-cell epitopes in the molecule. In this study, B-cell epitopes with a sensitivity and a specificity of 75% and 50%, respectively were predicted employing two different algorithms, BepiPred (linear epitopes) and DiscoTope (conformational epitopes). BepiPred predicted 48 B-cell linear epitopes and DiscoTope identified 57 residues which could account for 12 B-cell conformational epitopes. Regarding linear epitopes, ten of the GGA and FxxN motifs are included in epitope regions. These motifs can modulate the protein conformation implicated in adhesion or can modulate adhesin interaction with the eukaryotic receptors [@bib2].

Considering that the conformational epitopes are predicted using a 3D model, the reliability of the model must be taken into account, particularly in the predicted regions as conformational B-cell epitopes. Quality parameters given by Raptor X suggest an overall good quality model and RAMPAGE indicated that a high proportion (86%) of the residues predicted to be part of B-cell epitopes are in favored regions. On the other hand, ANOLEA analysis indicated that 45% of amino acids modeled by RaptorX and 85% of the residues in conformational epitopes have high energy. This is not surprising giving that most of the conformational epitopes were predicted in loops, which are a big challenge in protein modeling because they often represent insertions or deletions in homologue proteins, they are less confined by alignment derived restraints [@bib26], and they are usually structures with positive energy as predicted by ANOLEA or other servers [@bib46], [@bib47].

Simultaneously, BepiPred and DiscoTope predicted 9 Epitopes. The analysis performed using a bioinformatic approach contributed to identify numerous B-cell epitopes, and this correlates well with several previous studies where PmpD was able to elicit antibody production. Human serum studies have found anti-Pmps antibodies in *C. trachomatis*-infected patients [@bib2]. Moreover, Tan et al. indicate that some Pmps, including PmpD, may be more abundantly expressed or specifically exposed at the chlamydial surface to elicit a relatively stronger antibody response in adolescents with and without pelvic inflammatory disease (PID) [@bib11]. Several researchers have also shown the neutralizing ability of anti-PmpD antibodies [@bib15], [@bib16], [@bib18]. *In vitro* neutralization assays showed that serovars Ba, D, E, and L2 were more efficiently neutralized than serovars A, C, F, G and K by antibodies against recombinant PmpD [@bib16]. Although the high percentage of similarity among sequences, these differences could be related to little changes in specific amino acid. Then, defining epitope containing regions which are simultaneously conserved may allow choosing an immunogen able to induce neutralizing antibodies against all serovars. In this work, we identified six regions containing B- and T-cell epitopes, which additionally are conserved among serovars A-L. Besides being useful for vaccine design, predicting B-cell epitopes can contribute to the design of various diagnostic methods.

An adequate humoral response depends upon appropriate CD4+ T-cell response. Moreover, vaccines that induce cellular immune responses are essential for infections caused by intracellular pathogens. One of the major impediments in developing such vaccines includes difficulty in identifying relevant T-cell antigens that elicit protective cellular immunity [@bib48]. CD4+ T-cell-mediated immunity is a major component of host defense against *C. trachomatis* infection [@bib49] and to a lesser degree CD8+ T cells that recognize specific chlamydial antigens on MHC molecules [@bib2]. The identification of epitopes presented by MHC class I and II molecules should enable the development of an effective T-cell response against *C. trachomatis*. In this study, NetMHC and NetMHCII were employed for T-cell epitope prediction. Regarding the prediction of T-cell epitopes in the PmpD sequence performed, NetMHC predicted 271 T-cell epitopes of different lengths (9aa, 10aa, 11aa, 12aa) with weak affinity to MHC I molecules and 70 T-cell epitopes of different lengths (9aa, 10aa, 11aa, 12aa) with strong affinity to MHC I molecules ([Table 1](#tbl1){ref-type="table"}A). Moreover, NetMHCII predicted 742 ([Table 1](#tbl1){ref-type="table"}B) T-cell epitopes of 15aa with strong affinity and 2903 T-cell epitopes of 15aa with weak affinity to MHC class II molecules for the most prevalent MHC alleles in Argentina according to Perusco et al. [@bib40], as well as in North America and Europe (<http://www.allelefrequencies.net/default.asp>).These epitopes are abundant and homogeneously distributed throughout the protein sequence. Multiple alleles of MHC Class II are able to bind the same epitope. This was observed with several epitopes.

CD4+ and CD8+ T-cell immune responses in humans and mice are induced by *Chlamydia* infection, but the role of CD8+ T-cells in protective immunity is not clear. In the murine model, CD8+ T-cells contribute significantly to upper genial tract pathology [@bib50], [@bib51] and infertility [@bib52] but CD8+ T-cell are not necessary for clearing genital tract infection or protecting against reinfection [@bib53], [@bib54]. Therefore, the results obtained in this paper are promising due to the fact that we found more epitopes able to link with strong affinity to MHC class II with respect to epitopes predicted to bind to MHC class I, which are less and with weak affinity. The results allow choosing a PmpD sequence containing strong affinity to molecules of MHC class II, which would favor a desired response of CD4+ type against *C*. *trachomatis*.

Comparative analyses performed by simultaneous predictors identifies six regions that have lineal and conformational B-cell epitopes and affinity to MHC I (WB) and MHC II (SB) molecules. This allows selecting sequences that may activate T-cells and induce cytokine and antibody production which contribute in the resolution of a chlamydial infection. Nevertheless, experimental assessment of the immunogenic ability of such regions both *in vitro* and *in vivo* should be done to verify this prediction or to select the best fragment.

Conclusion {#sec5}
==========

PmpD has potential B-cell and T-cell epitopes distributed throughout the whole sequence. Numerous fragments could be selected as candidates for the design of a vaccine against *C*. *trachomatis*. To this end, in this study six regions containing both B-cell and T-cell epitopes were identified that may be used to generate both humoral and cellular response. These antigenic peptides can be valuable candidates for diagnostic as well as for therapeutic and preventive vaccines against *C*. *trachomatis.* Moreover, for vaccine design it would be important to select those regions that have the structural features of PmpD such as N-terminal GGA(I/L/V) and FxxN tetrapeptide repeats, an integrin-binding RGD motif, and a putative nuclear localization signal besides both B-cell and T-cell epitopes.

Selected fragments of PmpD that contains B- and T-cell epitopes in conjunction with effective adjuvants and/or delivery systems may contribute to the development of an effective chlamydial vaccine that elicits a Th1-mediated and humoral protective immune response that does not induce adverse immunopathologies. The data obtained will be utilized to delineate a series of immunization strategies. Among them: the synthesis of single epitopes that could be administered as unique or in combination, the design of a multi-epitope chimeric molecule or the selection of fragments containing several immunogenic regions.

The results of our study provide computational data for the identification and screening of epitopes in PmpD, and may be used for the development of epitope vaccines that have an enhanced safety and efficacy.
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